Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05212701
Other study ID # REP0121
Secondary ID 2021-000382-32
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date April 19, 2022
Est. completion date July 2024

Study information

Verified date January 2023
Source Dompé Farmaceutici S.p.A
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Primary objective: • To assess the efficacy of reparixin compared to placebo in limiting CRF in adult patients with locally advanced or metastatic breast cancer undergoing single-agent taxane chemotherapy, using FACITFatigue scale. The secondary objectives are: - To evaluate change in Quality of Life in the two treatment arms - To assess the percentage of patients treated with reparixin compared to placebo delaying and discontinuing chemotherapy - To assess Patient Global Impression of Severity (PGI-S) score and Patient Global Impression of Change (PGI-C) score associated with reparixin compared to placebo - To assess the effect of reparixin compared to placebo on ECOG PS - To assess the effects of reparixin vs placebo on Objective Response Rate (ORR), Progression Free Survival (PFS), Overall Survival (OS) The safety objective is: • To assess the safety and tolerability of reparixin in adult patients undergoing taxane-containing chemotherapy. The pharmacokinetic (PK) objective is: • To define the PK profile of orally administered reparixin, its metabolites (DF2243Y, DF2188Y, ibuprofen) and concomitant antineoplastic agents (paclitaxel, or nab-paclitaxel or docetaxel) in adult patients with locally advanced or metastatic breast cancer.


Description:

This is a phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled study. It will evenly randomize 68 evaluable men and women adult patients with CRF in locally advanced or metastatic breast cancer who are candidates to start single-agent taxane chemotherapy (paclitaxel, nab-paclitaxel or docetaxel). CRF will be assessed at baseline on a scale from 0 - 10 (with 10 being most severe), enrolling any patient who report a score of 1 - 6. Recruitment will be competitive among the study sites, until the planned number of patients is randomized. Patients will be assigned (1:1) to receive either oral reparixin treatment (1200 mg t.i.d. - treatment group) or masked placebo t.i.d. (control group). Randomization will be stratified by site and according to the type of chemotherapy (paclitaxel vs docetaxel vs nab-paclitaxel). Sparse blood samples will be collected in the whole population for reparixin (and metabolites), docetaxel, nab-paclitaxel, paclitaxel PK analysis. Reparixin or placebo will be administered for 16 weeks or until disease progression, withdrawal of consent or unacceptable toxicity, whichever occurs first. Following the completion of the treatment, or after premature discontinuation during the double-blind phase the patients will be followed up for safety assessments for an additional 30 days after last study therapy administration and will be followed for progressive disease and survival until twelve months after last enrolled subject off treatment, or until trial is terminated for other reasons, whatever occurs first. Number of Patients Sixty-eight (68) evaluable adult patients with CRF with locally advanced or metastatic breast cancer who are candidates to receive single-agent taxane chemotherapy will be included in the study. Assuming that 10% of subjects will not be evaluable for primary analysis, a total of approximately 76 subjects is expected to be enrolled.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date July 2024
Est. primary completion date June 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 1. Provide written informed consent before the initiation of any study-specific procedures - 2. Male or female =18 years of age - 3. Pathologically documented locally advanced (not amenable to surgical resection) or metastatic HER2-negative breast cancer - 4. Candidate to receive cycle 1 of treatment with single-agent taxane-based chemotherapy (paclitaxel, nab-paclitaxel, docetaxel) - 5. CRF score from 1 to 6 on a numeric rating scale (NRS) from 0 to 10, where 0 = no fatigue, 10 = worst possible fatigue, during the previous 24 hours and lasting for a minimum of 4 days - 6. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2 - 7. Life expectancy of at least 6 months as estimated by the investigator - 8. Able to swallow and retain oral medication (intact tablet) - 9. Adequate organ function (defined by the following parameters): 1. Serum creatinine < 140 µmol/L (< 1.6 mg/dL) or creatinine clearance > 60 mL/min 2. Serum hemoglobin = 11 g/dL; absolute neutrophil count = 1.5 x 109/L; platelets = 100 x 109/L. 3. Serum bilirubin = upper limit of normal (ULN), except patients with Gilbert's syndrome. 4. Serum Alanine aminotransferase (ALT), aspartate transaminase (AST) = 1.5 x ULN 5. Alkaline phosphatase = 2.5 x ULN 6. prothrombin time (PT) or activated partial thromboplastin time (aPTT, PTT) =ULN - 10. No known hepatitis B virus (not due to immunization), hepatitis C virus, human immunodeficiency virus-I and -II positive status - 11. If a female of childbearing potential, have a negative serum ß-human chorionic gonadotropin (ß-hCG) serum pregnancy test and use a highly effective method to avoid pregnancy for the duration of the trial and for at least 6 months after completion of docetaxel, paclitaxel or nab-paclitaxel therapy. Males of reproductive potential should use effective contraception during treatment and for 6 months after the last dose of docetaxel, paclitaxel or nab-paclitaxel Exclusion Criteria: - 1. More than 1 prior systemic chemotherapy for advanced disease. Patients may have received hormone therapy and biological therapy (e.g. CDK4/6 inhibitors), either alone or in combination - 2. Malabsorption syndrome or disease significantly affecting gastrointestinal function including but not limited to gastrectomy or gastric outlet obstruction - 3. History or evidence of neurological or psychiatric disorder or any other concurrent medical condition or disease that, in the opinion of the investigator or Medical Monitor may influence understanding of study and informed consent procedures, would pose a risk to subject safety or would interfere with the study evaluation, procedures or completion - 4. Positive severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) antigenic test performed through nasal swab - 5. Treatment with any investigational agent within at least 28 days or 5 half-lives (whatever is shorter) prior to Visit 1, recovered from previous treatment toxicity to Grade1 or better - 6. Brain metastases that are untreated or symptomatic, or require any radiation, surgery, or continued steroid therapy to control symptoms from brain metastases - 7. Treatment with oral morphine greater than 60 mg a day or equivalent - 8. Other causes of fatigue, including, but not restricted to: 1. untreated hypothyroidism 2. pituitary disorder 3. insomnia 4. alcohol abuse 5. uncontrolled pain as defined by pain intensity greater than 3 on a NRS (0-10) 6. chronic >G2 anemia 7. uncontrolled cardiac disease or cardiovascular disorders 8. acute infections 9. major depressive disorder 10. uncontrolled neurological disorders - 9. Concomitant use of other medications/dietary supplements for fatigue - 10. Concomitant use of cannabidiol (CBD) or Tetrahydrocannabinol (THC). - 11. Any other invasive malignancy from which the patient has been disease-free for less than 5 years with the exception of curatively treated basal or squamous cell skin cancer - 12. Patients who are committed to an institution by virtue of an order issued either by the judicial or the administrative authorities - 13. Patients who are employees of the sponsor or investigator or otherwise dependent on them - 14. History of: 1. intolerance or hypersensitivity to paclitaxel, nab-paclitaxel, docetaxel or any other concomitant drug used in the study 2. intolerance or hypersensitivity to ibuprofen or to non-steroidal anti-inflammatory drug (NSAIDs) 3. intolerance or hypersensitivity to more than one medication belonging to the class of sulfonamides, such as sulfamethazine, sulfamethoxazole, sulfasalazine, nimesulide or celecoxib; hypersensitivity to sulphanilamide antibiotics alone (e.g. sulfamethoxazole) does not qualify for exclusion 4. lactase deficiency, galactosaemia or glucose-galactose malabsorption 5. documented allergic reaction or severe reaction of any kind to dairy products - 15. Pregnancy or lactation or unwillingness to use adequate method of birth control. Effective contraceptive measures include intrauterine device (IUD), bilateral tubal occlusion, vasectomised partner, sexual abstinence. - 16. Concomitant use of ibuprofen or CYP2C9 inhibitors/inducers and inability to pause these drugs during the study - 17. Concurrent use of NSAIDs or inability to stop NSAIDs during the treatment period - 18. Any contraindications to NSAIDs including but not limited to previous experience of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. - 19. A history of gastrointestinal bleeding or perforation related to previous NSAIDs therapy or an active or history of recurrent peptic ulcer/haemorrhage, coagulation disturbances

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Reparixin
The oral tablets of the investigational product (IP) will be administered with water prior to the start of the anticancer treatment infusion on Day 1 Cycle 1 and then administered approximately every eight hours (± 2 h) with a glass of water (about 250 mL) and a light meal or snack (it is preferable that reparixin is taken with food).
Placebo
The oral tablets of masked placebo will be administered with water prior to the start of the anticancer treatment infusion on Day 1 Cycle 1 and then administered approximately every eight hours (± 2 h) with a glass of water (about 250 mL) and a light meal or snack

Locations

Country Name City State
Germany Universitätsklinikum Düsseldorf, Frauenklinik Duesseldorf
Germany Kliniken Essen-Mitte, Klinik für Senologie/ Interdisziplinäres Brustzentrum Essen
Germany Praxis für Interdisziplinäre Onkologie & Hämatologie Freiburg
Germany Mammazentrum Hamburg am Krankenhaus Jerusalem Hamburg
Germany Klinikum Ernst von Bergmann, Frauenklinik Potsdam
Italy IRCCS Oncologico Istituto Tumori Giovanni Paolo II Bari
Italy Azienda Ospedaliero Universitaria di Bologna - Policlinico S. Orsola-Malpighi Bologna
Italy ASST-Spedali Civili di Brescia Brescia
Italy E.O. Ospedali Galliera Genova
Italy Istituto Scientifico Romagnolo per lo Studio e La Cura dei Tumori SRL IRCCS Meldola (FC)
Italy IRCCS - Istituto Europeo di Oncologia Milano
Italy Azienda Ospedaliera di Perugia, Ospedale Santa Maria della Misericordia Perugia
Italy Azienda Ospedaliera Universitaria Pisana Pisa
Italy "Azienda Unità Sanitaria Locale della Romagna Ospedale Infermi di Rimini" Rimini
Italy "Azienda Ospedaliero Universitaria Sant'Andrea " Roma
Italy Fondazione Policlinico Universitario A. Gemelli, IRCCS Roma
Italy Istituti Fisioterapici Ospitalieri- IFO - Istituto Regina Elena Roma
Italy Ospedale Giuseppe Mazzini di Teramo Teramo
Italy A.O. "Pia Fondazione Cardinale Panico" Tricase
United States Waverly Hematology Cary North Carolina
United States Florida Cancer Specialists and Research Institute LLC Fort Myers Florida
United States University of Minnesota Medical Center, Fairview Minneapolis Minnesota
United States Tennessee Oncology, PLLC Nashville Tennessee
United States Florida Cancer Specialists and Research Institute LLC Saint Petersburg Florida

Sponsors (1)

Lead Sponsor Collaborator
Dompé Farmaceutici S.p.A

Countries where clinical trial is conducted

United States,  Germany,  Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in FACIT-F score The Functional Assessment of Chronic Illness Therapy - fatigue (FACIT-fatigue) scale is a 13-item instrument designed to assess fatigue/ tiredness and its impact on daily activities and functioning in a number of chronic diseases. The instrument includes items such as tiredness, weakness, listlessness, lack of energy, and the impact of these feelings on daily functioning (e.g., sleeping, and social activities).
The FACIT-fatigue scale is a 13-item patient-reported measure of fatigue where items are scored on a 0 - 4 response scale with anchors ranging from "Not at all" to "Very much so". To score the FACIT-fatigue, all items are summed to create a single fatigue score with a range from 0 to 52, where higher scores represent better functioning or less fatigue.
week 16
Secondary Change from baseline in FACIT-F score The Functional Assessment of Chronic Illness Therapy - fatigue (FACIT-fatigue) scale is a 13-item instrument designed to assess fatigue/ tiredness and its impact on daily activities and functioning in a number of chronic diseases. The instrument includes items such as tiredness, weakness, listlessness, lack of energy, and the impact of these feelings on daily functioning (e.g., sleeping, and social activities).
The FACIT-fatigue scale is a 13-item patient-reported measure of fatigue where items are scored on a 0 - 4 response scale with anchors ranging from "Not at all" to "Very much so". To score the FACIT-fatigue, all items are summed to create a single fatigue score with a range from 0 to 52, where higher scores represent better functioning or less fatigue.
weeks 4, 8 and 12
Secondary EQ-5D-5L score The EQ-5D-5L consists of 2 pages: the EQ-5D-5L descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box of the most appropriate statement in each of the 5 dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the 5 dimensions can be combined into a 5-digit number that describes the patient's health state.The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS is used as a quantitative measure of health outcome that reflect the patient's own judgment. day 1 of each 21- or 28-day cycle, off treatment visit (or withdrawal), which means up to 70 weeks
Secondary Patient Global Impression of Severity (PGI-S) score The PGI-S is designed to capture subject's perception of overall symptom severity at the time of completion on a 5-point categorical response scale: "Please choose the response below that best describes the severity of your fatigue over the past week" and is scored from 1 to 5, with 1 indicating "None", 2 "Mild", 3 "Moderate", 4 "Severe", 5 "Very Severe". The higher the score, the worse the outcome. day 1 of each 21- or 28-day cycle, off treatment visit (or withdrawal) which means up to 70 weeks
Secondary Patient Global Impression of Change (PGI-C) score The PGI-C is designed to capture the subject's perception of change in their overall symptom severity from baseline until the time of completion. Change in severity is captured using a 5- point scale: "Please choose the response below that best describes the overall change in your fatigue since you started receiving the taxane-based chemotherapy" and is scored from 1 to 5, with 1 indicating "Much better", 2 "A little better", 3 "No change", 4 "A little worse", 5 "Much worse". The higher the score, the worse the outcome. day 1 of each 21- or 28-day cycle except for cycle 1, off treatment visit (or withdrawal), which means up to 70 weeks
Secondary Proportion of patients delaying next administration of chemotherapy due to CRF Proportion of patients delaying next dosing of chemotherapy due to chronic renal failure (CRF) throughout the study, up to 70 weeks
Secondary Proportion of patients discontinuing chemotherapy due to CRF Proportion of patients discontinuing chemotherapy due to chronic renal failure (CRF) throughout the study, up to 70 weeks
Secondary Change in Eastern Cooperative Oncology Group Performance Status (ECOG PS) ECOG PS is graded as follow:
0 Fully active, able to carry on all pre-disease performance without restriction
Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work
Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours
Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours
Completely disabled; cannot carry on any selfcare; totally confined to bed or chair
Dead The higher the score, the worse the outcome.
baseline, day 1 of each 21- or 28-day chemotherapy cycle, off treatment visit (or withdrawal) which means up to 70 weeks
Secondary Overall Response Rate (ORR) ORR is defined as the proportion of patients with best overall response of CR or PR according to RECIST 1.1. Through study treatment, up to 70 weeks
Secondary Progression Free Survival (PFS) PFS is defined as the time from the date of randomization until the date of the first documented progression or death due to any cause. PFS will be assessed based on local investigator assessment per RECIST 1.1. Up to 12 months post-treatment
Secondary Overall Survival (OS) OS is defined as the time from date of first administration of study treatment until date of death due to any cause Up to 12 months post-reparixin discontinuation
See also
  Status Clinical Trial Phase
Completed NCT04959214 - The Effect Of Progressıve Relaxatıon Exercıses N/A
Recruiting NCT04984226 - Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD Phase 2
Completed NCT04531891 - Utility and Validity of a High-intensity, Intermittent Exercise Protocol N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Completed NCT04960865 - Kinesio Taping and Calf Muscle Fatigue N/A
Completed NCT02948283 - Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia Phase 1
Recruiting NCT05344183 - Immediate and Short-term Effects of Low-level Laser N/A
Completed NCT04716049 - Effectiveness of Recovery Protocols in Elite Professional Young Soccer Players N/A
Completed NCT00060398 - Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer Phase 3
Recruiting NCT05241405 - Evaluation of the Impact of Taking American Ginseng for 8 Weeks on Fatigue in Patients Treated for Localized Breast Cancer N/A
Active, not recruiting NCT06074627 - Radicle Energy2: A Study of Health and Wellness Products on Fatigue and Other Health Outcomes N/A
Completed NCT03943212 - The Effect of Blood Flow Rate on Dialysis Recovery Time in Patients Undergoing Maintenance Hemodialysis N/A
Recruiting NCT05567653 - Effects of Probiotics on Gut Microbiota, Endocannabinoid and Immune Activation and Symptoms of Fatigue in Dancers N/A
Active, not recruiting NCT05636696 - COMPANION: A Couple Intervention Targeting Cancer-related Fatigue N/A
Not yet recruiting NCT05863897 - e-COGRAT: A Blended eHealth Intervention for Fatigue Following Acquired Brain Injury N/A
Not yet recruiting NCT05002894 - Effect of Pilates Exercises On Fatigue In Post Menopausal Women N/A
Recruiting NCT04091789 - Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea Phase 2
Completed NCT02911649 - Reducing Sedentary Behaviour With Technology N/A
Completed NCT02321358 - Trial of a Behavior Change Intervention to Increase Aerobic and Resistance Exercise and Quality of Life in Older Prostate and Breast Cancer Survivors N/A
Completed NCT03216616 - Guided Self-Management Intervention Targeting Fatigue in Rheumatic Inflammatory Diseases N/A